智通财经APP讯，佰金生命科学(01466)发布公告，公司正进行若干附属公司，即汇宝丰投资控股有限公司、民生创见有限公司、荟宝珠饰有限公司、民生珠宝(香港)有限公司及宝荟珠宝有限公司(统称香港附属公司)，以及汇宝丰珠宝(深圳)有限公司(中国附属公司，连同香港附属公司，合称附属公司)的董事及监事变更。
上述相关变更包括(i)委任张诗敏和苏耀耀为各香港附属公司的董事;(ii) 别委任李松和苏耀耀为中国附属公司的董事和监事;(iii)罢免各香港附属公司作为唯一董事的陈志伟;及(iv)罢免中国附属公司董事许超生、陈木胜及韩继平及监事熊英(附属公司管理层变更)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.